Cargando…

Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activat...

Descripción completa

Detalles Bibliográficos
Autor principal:	Rotte, Anand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567914/ https://www.ncbi.nlm.nih.gov/pubmed/31196207 http://dx.doi.org/10.1186/s13046-019-1259-z

Ejemplares similares

Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary
por: Rotte, Anand
Publicado: (2023)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
por: Wu, Kongju, et al.
Publicado: (2019)

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
por: Tunger, Antje, et al.
Publicado: (2018)

Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
por: Nebot-Bral, Laetitia, et al.
Publicado: (2022)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

Correction: Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
Publicado: (2022)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
por: Puri, Sonam, et al.
Publicado: (2020)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review
por: Miller, Peter L., et al.
Publicado: (2020)

From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1—Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?
por: Wang, Lishi, et al.
Publicado: (2021)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
por: Qin, Shuang, et al.
Publicado: (2019)

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
por: Lee, Hyun Tae, et al.
Publicado: (2019)

SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis
por: Aghbash, Parisa Shiri, et al.
Publicado: (2021)

Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
por: Alimohammadi, Reza, et al.
Publicado: (2020)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
por: Hao, Yuwei, et al.
Publicado: (2022)

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers
por: Tuccilli, Chiara, et al.
Publicado: (2018)

A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets
por: Cai, Zongqiang, et al.
Publicado: (2021)

Blood PD-1(+)TFh and CTLA-4(+)CD4(+) T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis
por: Aldridge, Jonathan, et al.
Publicado: (2021)

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
por: Quezada, S A, et al.
Publicado: (2013)

Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
por: Xu, Li, et al.
Publicado: (2022)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
por: Yang, Hui, et al.
Publicado: (2013)

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
por: Youlin, Kuang, et al.
Publicado: (2012)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

Expression of PD‐L1 and CTLA‐4 in female urethral carcinoma
por: Ninomiya, Sahoko, et al.
Publicado: (2018)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
por: Feng, Yuqian, et al.
Publicado: (2021)

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
por: Huang, Shuang, et al.
Publicado: (2023)

Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis
por: Cho, Hyosun, et al.
Publicado: (2017)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
por: Porcellato, Ilaria, et al.
Publicado: (2021)

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer
por: Guo, Luyong, et al.
Publicado: (2022)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
por: Werner, Jan-Michael, et al.
Publicado: (2019)

Murine peripheral blood prognostic biomarkers for tumor survival following combination aCTLA-4 and aPD-1 treatment
por: Hilgart-Martiszus, Ian, et al.
Publicado: (2015)

PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis
por: He, Runzhi, et al.
Publicado: (2022)

Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations
por: Lemaire, Vincent, et al.
Publicado: (2021)

Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer: A meta-analysis
por: Zhang, Pei-Pei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s0okuof7ibvr5sutlkqpigahd0